Founded in Bedminster, New Jersey, Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. Its core mission is to revolutionize the delivery of small molecule drugs, oligonucleotides, vaccines, peptides, and proteins through its proprietary lipid nano-crystal (LNC) platform. The company focuses on developing innovative therapies to address significant unmet medical needs, particularly in the areas of infectious diseases and cardiometabolic conditions.
Matinas BioPharma has notable affiliations with experts like Dr. David S. Perlin, a recognized authority in antifungal treatments. The company has achieved significant milestones, including presenting new in vitro data at prominent conferences such as TIDES USA and the ASGCT Annual Meeting. These achievements underscore its impact on advancing drug delivery technologies and enhancing therapeutic efficacy.
